

Mark Slee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9251449/publications.pdf>

Version: 2024-02-01

86
papers

6,162
citations

109321

35
h-index

71685

76
g-index

91
all docs

91
docs citations

91
times ranked

8330
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013, 45, 1353-1360.	21.4	1,213
2	Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. <i>Nature Genetics</i> , 2009, 41, 824-828.	21.4	501
3	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	7.4	336
4	Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. <i>Annals of Neurology</i> , 2011, 70, 897-912.	5.3	314
5	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	7.6	281
6	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e48078.	2.5	166
7	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	7.6	162
8	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746.	3.0	148
9	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	5.3	143
10	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617.	7.6	140
11	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014, 82, 1204-1211.	1.1	138
12	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	10.2	134
13	The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. <i>Human Molecular Genetics</i> , 2010, 19, 2134-2143.	2.9	128
14	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686.	2.5	122
15	Multifocal motor neuropathy. <i>Neurology</i> , 2007, 69, 1680-1687.	1.1	111
16	Incidence and prevalence of NMOSD in Australia and New Zealand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 632-638.	1.9	108
17	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	7.6	94
18	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1133-1137.	1.9	76

#	ARTICLE	IF	CITATIONS
19	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522.	3.0	73
20	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	1.9	71
21	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890.	5.3	67
22	Data quality evaluation for observational multiple sclerosis registries. <i>Multiple Sclerosis Journal</i> , 2017, 23, 647-655.	3.0	64
23	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	1.9	63
24	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. <i>Multiple Sclerosis Journal</i> , 2012, 18, 974-982.	3.0	56
25	A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis. <i>PLoS ONE</i> , 2010, 5, e13454.	2.5	55
26	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643.	7.6	54
27	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.1	54
28	A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. <i>Human Molecular Genetics</i> , 2015, 24, 5644-5654.	2.9	53
29	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	3.0	52
30	The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease. <i>Clinical Immunology</i> , 2014, 151, 16-24.	3.2	49
31	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	1.9	49
32	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	3.7	43
33	Polymorphisms in the Receptor Tyrosine Kinase MERTK Gene Are Associated with Multiple Sclerosis Susceptibility. <i>PLoS ONE</i> , 2011, 6, e16964.	2.5	42
34	The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. <i>PLoS ONE</i> , 2013, 8, e59694.	2.5	38
35	CSF hypotension: A review of its manifestations, investigation and management. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 39-43.	1.5	38
36	The Kurtzke EDSS rank stability increases 4â€¦years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 305-310.	1.9	37

#	ARTICLE	IF	CITATIONS
37	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	3.0	37
38	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	3.0	36
39	Cladribine versus fingolimod, natalizumab and interferon Î² for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1617-1626.	3.0	36
40	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012, 318, 94-99.	0.6	35
41	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	2.0	35
42	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	2.5	35
43	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	3.0	34
44	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	5.3	34
45	Late effects of oxaliplatin-induced peripheral neuropathy (LEON)â€“cross-sectional cohort study of patients with colorectal cancer surviving at least 2Âyears. <i>Supportive Care in Cancer</i> , 2015, 23, 861-869.	2.2	33
46	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	7.6	32
47	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	3.0	30
48	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2017, 17, 312-318.	2.0	28
49	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. <i>Frontiers in Neurology</i> , 2020, 11, 537.	2.4	27
50	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480.	2.5	26
51	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	7.6	24
52	Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season. <i>Multiple Sclerosis Journal</i> , 2014, 20, 675-685.	3.0	23
53	Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. <i>Multiple Sclerosis Journal</i> , 2021, 27, 465-474.	3.0	23
54	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1847-1856.	1.5	22

#	ARTICLE	IF	CITATIONS
55	Neuromyelitis optica (Devic's disease) in a patient with syphilis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 268-271.	3.0	20
56	Resequencing and fine-mapping of the chromosome 12q13-14 locus associated with multiple sclerosis refines the number of implicated genes. <i>Human Molecular Genetics</i> , 2013, 22, 2283-2292.	2.9	20
57	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	9.0	20
58	Parkinsonism and dementia due to gliomatosis cerebri mimicking sporadic Creutzfeldt-Jakob disease (CJD). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 283-284.	1.9	19
59	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1857-1865.	1.5	19
60	A novel mitochondrial DNA deletion producing progressive external ophthalmoplegia associated with multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1318-1324.	1.5	18
61	Identity-by-Descent Mapping to Detect Rare Variants Conferring Susceptibility to Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e56379.	2.5	18
62	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 11-19.	2.0	17
63	The clinical profile of NMOSD in Australia and New Zealand. <i>Journal of Neurology</i> , 2020, 267, 1431-1443.	3.6	17
64	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1835-1846.	1.5	15
65	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.	3.3	12
66	A Neuroethics Framework for the Australian Brain Initiative. <i>Neuron</i> , 2019, 101, 365-369.	8.1	11
67	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	3.0	11
68	Muscle-specific kinase antibody positive myasthenia gravis and multiple sclerosis co-presentation: A case report and literature review. <i>Journal of Neuroimmunology</i> , 2013, 264, 130-133.	2.3	10
69	Fluctuations of MS births and UV-light exposure. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 301-308.	2.1	10
70	A new era in the treatment of multiple sclerosis. <i>Medical Journal of Australia</i> , 2015, 203, 139-141.	1.7	10
71	Relapsing encephalopathy with headache: an unusual presentation of isolated intracranial neurosarcoidosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 770-771.	1.9	8
72	The effectiveness of natalizumab vs fingolimod—A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	2.0	8

#	ARTICLE	IF	CITATIONS
73	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	5.9	8
74	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 722237.	2.4	8
75	A Case of Valproate Induced Hyperammonemic Encephalopathy. <i>Case Reports in Medicine</i> , 2011, 2011, 1-2.	0.7	7
76	Relapsing necrotising encephalomyelopathy due to <i>RANBP2</i> mutation. <i>Practical Neurology</i> , 2019, 19, 360-363.	1.1	7
77	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. <i>Multiple Sclerosis Journal</i> , 2022, 28, 958-969.	3.0	6
78	Speech-activated myoclonus: An uncommon form of action myoclonus. <i>Movement Disorders</i> , 2005, 20, 1120-1126.	3.9	5
79	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560019.	1.0	5
80	NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. <i>Journal of Neurology</i> , 2022, 269, 836-845.	3.6	5
81	Flow cytometry identifies an early stage of platelet apoptosis produced by agonists of the P2X1 and P2X7 receptors. <i>Platelets</i> , 2022, 33, 621-631.	2.3	5
82	Clinical, electrophysiological and genetic features of a large Australian family with paramyotonia congenita. <i>Medical Journal of Australia</i> , 2009, 190, 456-456.	1.7	3
83	Clinical, electrophysiological and genetic features of a large Australian family with paramyotonia congenita. <i>Medical Journal of Australia</i> , 2009, 190, 334-336.	1.7	3
84	EXPOSURE TO INTERFERON- β THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A17.2-A17.	1.9	2
85	The Northern Territory Medical Program “growing our own in the NT. <i>Rural and Remote Health</i> , 2019, 19, 4671.	0.5	2
86	Response to treatment in NMOSD: the Australasian experience. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 58, 103408.	2.0	0